How can we conduct studies in the ACLF patient population? Come discuss with Dr. Kulkarni, an author of the recent Hepatology Communications article “Midodrine versus placebo in patients with acute-on-chronic liver failure with ascites—A randomized trial (MIDAS trial).” Read the article here: https://doi.org/10.1097/HC9.0000000000000966
Access to transportation is a key social determinant of health outcomes and a required component of liver transplant eligibility. Come discuss with Dr. Zhou, an author of the recent Liver Transplantation article “A pilot randomized controlled trial of a transportation assistance program in liver transplant (TAP-LT) candidates.” Read the article here: https://doi.org/10.1097/LVT.0000000000000832.
The WHO approved the Assembly’s first ever resolution on steatotic liver disease on May 22, 2026. How can independent national monitoring drive implementation? Come discuss with Dr. Lazarus, an author of the recent HEPATAOLOGY commentary “AASLD’s opportunity to lead national monitoring of the World Health Assembly resolution on steatotic liver disease.” Read the article here: https://doi.org/10.1097/HEP.0000000000001861.
Developed by 20 leading North American experts representing hepatology, medical oncology, surgery, radiology, and radiation oncology, BEACON-HCC provides a contemporary framework to modernize treatment decision-making for hepatocellular carcinoma, reflecting current clinical practice and the rapidly expanding range of therapies available to patients. Come discuss with Dr. Singal, the lead author on the landmark multidisciplinary consensus published in HEPATOLOGY. Read the article here: https://doi.org/10.1097/HEP.0000000000001834
Is group-based telehealth behavioral intervention feasible? Come discuss with Dr. Evon an author of the Hepatology Communications article “Group-based telehealth stress management—lifestyle interventions are feasible for patients with chronic liver disease.” Read the article here: https://doi.org/10.1097/HC9.0000000000000849.
Join us for an interactive conversation with Dr. Hoofnagle on LiverTox, the NIH’s authoritative online resource on drug-induced liver injury. The database provides comprehensive and unbiased information about drug induced liver injury caused by prescription and nonprescription drugs, herbal and dietary supplements. Explore the resource here: livertox.nih.gov.
Alcohol-associated harm remains a major, largely preventable driver of global morbidity, mortality, and societal costs, and alcohol-associated liver disease is a major consequence of long-term exposure. Come discuss with Dr. Diaz, an author of the recent Hepatology Communications review article “The global epidemiology of alcohol-associated liver disease.” Read the article here: https://doi.org/10.1097/HC9.0000000000000947
Come discuss the latest AASLD AGA practice guideline on management of primary biliary cholangitis with writing group member Dr. Bittermann. What has changed?
The hepatic sinusoid is increasingly recognized as a multicellular, spatially organized and therapeutically actionable regulatory niche rather than merely a specialized microvascular bed. Come discuss with Dr. Gracia-Sancho, the author of the recent HEPATOLOGY review article “The hepatic sinusoid as a regulatory niche: From cellular specialization to precision hepatology.” Read the article here: https://doi.org/10.1097/HEP.0000000000001870.
How has robotic liver transplantation impacted the field? Come discuss with Dr. Khan, the author of the recent Liver Transplantation review article “Robotic liver transplant: Current evidence, technical nuances, and potential pitfalls.” Read the article here: https://doi.org/10.1097/LVT.0000000000000946